title: Budget Impact Analysis of the Use of Crizotinib for Non-Small Cell Lung Cancer and ALK+ Mutation in the Two Main Public Health Care Institutions in Mexico.
authors.affiliation: Pfizer S. A. de C. V., Ciudad de México, Mexico.
authors.forename: L
authors.initials: L
authors.lastname: Guirant-Corpi
authors.affiliation: Pfizer S. A. de C. V., Ciudad de México, Mexico.
authors.forename: E
authors.initials: E
authors.lastname: Muciño-Ortega